Capital Impact Advisors LLC trimmed its holdings in Natera Inc (NASDAQ:NTRA) by 36.8% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 81,783 shares of the medical research company’s stock after selling 47,558 shares during the quarter. Capital Impact Advisors LLC owned 0.13% of Natera worth $1,811,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in NTRA. Schwab Charles Investment Management Inc. lifted its holdings in shares of Natera by 11.7% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 172,518 shares of the medical research company’s stock worth $1,600,000 after acquiring an additional 18,051 shares during the last quarter. Northern Trust Corp increased its stake in shares of Natera by 1.5% in the first quarter. Northern Trust Corp now owns 375,674 shares of the medical research company’s stock worth $3,483,000 after buying an additional 5,428 shares during the period. A.R.T. Advisors LLC purchased a new position in shares of Natera in the first quarter worth $164,000. Millennium Management LLC increased its stake in shares of Natera by 218.7% in the first quarter. Millennium Management LLC now owns 316,222 shares of the medical research company’s stock worth $2,931,000 after buying an additional 216,987 shares during the period. Finally, Essex Investment Management Co. LLC purchased a new position in shares of Natera in the second quarter worth $3,281,000. Hedge funds and other institutional investors own 66.31% of the company’s stock.
Shares of NASDAQ NTRA opened at $21.36 on Friday. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of -3.32. Natera Inc has a 52 week low of $8.60 and a 52 week high of $29.62. The firm has a market capitalization of $1.30 billion, a P/E ratio of -8.90 and a beta of 2.24.
Several research analysts recently commented on the stock. Zacks Investment Research raised shares of Natera from a “sell” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Saturday, October 13th. TheStreet downgraded shares of Natera from a “c-” rating to a “d+” rating in a research note on Tuesday, October 9th. JPMorgan Chase & Co. assumed coverage on shares of Natera in a research note on Friday, October 5th. They issued a “neutral” rating and a $26.00 target price on the stock. Morgan Stanley lifted their target price on shares of Natera from $21.00 to $41.00 and gave the stock an “overweight” rating in a research note on Friday, September 28th. Finally, BidaskClub downgraded shares of Natera from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $26.00.
In other Natera news, insider Jonathan Sheena sold 166,667 shares of the business’s stock in a transaction on Tuesday, October 16th. The shares were sold at an average price of $20.66, for a total transaction of $3,443,340.22. Following the transaction, the insider now directly owns 372,583 shares of the company’s stock, valued at approximately $7,697,564.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Matthew Rabinowitz sold 403,462 shares of the business’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $24.90, for a total transaction of $10,046,203.80. Following the transaction, the chief executive officer now directly owns 1,701,686 shares in the company, valued at $42,371,981.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 2,014,988 shares of company stock worth $48,674,710. Insiders own 13.18% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Read More: Asset Allocation and Your Retirement
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.